BioLineRx Bilan de santé

Santé financière contrôle des critères 5/6

BioLineRx possède un total de capitaux propres de $8.5M et une dette totale de $27.8M, ce qui porte son ratio d'endettement à 326.9%. Son actif total et son passif total sont $52.7M et de $44.2M.

Informations clés

326.9%

Ratio d'endettement

US$27.80m

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$29.17m
Fonds propres	US$8.51m
Total du passif	US$44.24m
Total des actifs	US$52.74m

Mises à jour récentes de la santé financière

Recent updates

BioLineRx, GenFleet to co-develop Motixafortide treatment for a type of pancreatic cancer

Jun 29

BioLineRx: A Top Candidate For A Takeover Before 2022 Ends

Jun 30

biolinerx EPS beats by $0.17

May 26

BioLineRx (BLRX) shares rocket 73% on positive Motixafortide data in multiple myeloma

May 04

BioLineRx jumps 22% on promising triple combination data of motixafortide in pancreatic cancer

Dec 16

biolinerx EPS beats by $0.32

Nov 23

BioLineRx launches early-stage study with lead asset in COVID-19 related respiratory distress

Nov 18

BioLineRx launches mid-stage combo study in first-line pancreatic cancer

Oct 29

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de BLRX ( $37.8M ) dépassent ses passifs à court terme ( $25.0M ).

Passif à long terme: Les actifs à court terme de BLRX ( $37.8M ) dépassent ses passifs à long terme ( $19.3M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: BLRX dispose de plus de liquidités que de sa dette totale.

Réduire la dette: Le ratio d'endettement de BLRX est passé de 23.4% à 326.9% au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: BLRX dispose d'une piste de trésorerie suffisante pour 12 mois sur la base du dernier rapport flux de trésorerie disponible, mais a depuis levé des capitaux supplémentaires.

Prévisions de trésorerie: BLRX dispose d'une marge de trésorerie suffisante pour plus de 3 ans si le flux de trésorerie disponible continue de diminuer à un taux historique de 0.2 % chaque année

BioLineRx Bilan de santé

Santé financière contrôle des critères 5/6

Informations clés

Mises à jour récentes de la santé financière

BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification

BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification

Recent updates

BioLineRx Ltd. has filed a Follow-on Equity Offering in the amount of $8.998765 million.

BioLineRx Ltd. to Report Q3, 2024 Results on Nov 25, 2024

Biolinerx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for Cd34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease At Ash 2024

BioLineRx Ltd. Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide

BioLineRx Ltd., Annual General Meeting, Oct 01, 2024

BioLineRx Ltd. to Report Q2, 2024 Results on Aug 15, 2024

BioLineRx Ltd Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization For Gene Therapy Applications in Sickle Cell Disease

BioLineRx Ltd. Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer at American Society of Clinical Oncology

BioLineRx Ltd. to Report Q1, 2024 Results on May 28, 2024

BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification

BioLineRx Ltd. Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists Including APHEXDA® (Motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting

BioLineRx Ltd. to Report Fiscal Year 2023 Results on Mar 26, 2024

BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (Bl-8040) Suitable for Large Scale Production

Biolinerx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer

BioLineRx Ltd. Announces Acceptance of Two Poster Presentations on APHEXDA®? (Motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT®?

BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease

BioLineRx Ltd. Appoints Gal Cohen to Its Board as a Class I Director

BioLineRx Ltd. to Report Q3, 2023 Results on Nov 20, 2023

BioLineRx Ltd. announced that it has received $14.6 million in funding

Biolinerx Ltd. Announces Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide in First-Line Pancreatic Cancer (Pdac)

BioLineRx Ltd Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma

BioLineRx Ltd. to Report Q2, 2023 Results on Aug 30, 2023

BioLineRx Ltd. Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic Pancreatic Cancer Based on Preliminary Data from Single-Arm Pilot Phase

BioLineRx Ltd., Annual General Meeting, Aug 07, 2023

BioLineRx Ltd. to Report Q1, 2023 Results on May 24, 2023

Rosen Law Firm Encourages Biolinerx Ltd. Investors with Losses to Secure Counsel Before Important Deadline

Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of BioLineRx Ltd

BioLineRx Ltd. Appoints Tami Rachmilewitz, M.D., as Chief Medical Officer

BioLineRx Ltd. Announces Results from Phase 1/2a Study of Investigational Anti-Tumor Vaccine AGI-134 in Metastatic Solid Tumors

BioLineRx Ltd. Announces U.S. FDA Acceptance of New Drug Application for Aphexda® (Motixafortide) in Stem Cell Mobilization

BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification

Biolinerx Ltd. Announces U.S. Commercialization Plan for Aphexda (Motixafortide) in Stem Cell Mobilization

BioLineRx stock slips on $15M securities offering

BioLineRx Announces Submission of New Drug Application to U.S. Food and Drug Administration for Motixafortide in Stem Cell Mobilization

BioLineRx files for FDA approval of motixafortide in stem cell mobilization

biolinerx GAAP EPS of -$0.01 beats by $0.08

BioLineRx Ltd. to Report Q2, 2022 Results on Aug 16, 2022

BioLineRx, GenFleet to co-develop Motixafortide treatment for a type of pancreatic cancer

BioLineRx Ltd. Appoints Holly W. May as its Chief Commercial Officer

BioLineRx Ltd., Annual General Meeting, Jul 03, 2022

BioLineRx Ltd. to Report Q1, 2022 Results on May 11, 2022

BioLineRx Ltd. Announces Additional Positive Results from Pharmacoeconomic Study Comparing Motixafortide + G-CSF to Plerixafor + G-CSF in Stem Cell Mobilization

BioLineRx Announces Completion of Enrollment of Phase 1/2A Study of Innovative Intratumoral Cancer Vaccine, AGI-134, in Unresectable Metastatic Solid Tumors

BioLineRx Ltd. Announces Successful Completion of Pre-NDA Meeting with FDA for Motixafortide for Stem Cell Mobilization in Multiple Myeloma Patients

BioLineRx: A Top Candidate For A Takeover Before 2022 Ends

biolinerx EPS beats by $0.17

BioLineRx Ltd. Announces Positive Top-Line Results from GENESIS Phase 3 Trial of Motixafortide in Stem-Cell Mobilization for Autologous Bone Marrow Transplantation in Multiple Myeloma Patients

BioLineRx (BLRX) shares rocket 73% on positive Motixafortide data in multiple myeloma

BioLineRx Ltd. to Report Fiscal Year 2020 Results on Feb 23, 2021

BioLineRx Ltd. Announces Final Results from Phase 2a COMBAT/KEYNOTE-202 Triple Combination Study of Motixafortide in Second Line Metastatic Pancreatic Cancer (PDAC)

BioLineRx jumps 22% on promising triple combination data of motixafortide in pancreatic cancer

biolinerx EPS beats by $0.32

BioLineRx Ltd. to Report Q3, 2020 Results on Nov 23, 2020

BioLineRx Ltd. Announces Initiation of Phase 1B Clinical Trial in Patients with Acute Respiratory Distress Syndrome Secondary to Covid-19 and Other Respiratory Viral Infections

BioLineRx launches early-stage study with lead asset in COVID-19 related respiratory distress

BioLineRx Announces Positive Results from Interim Analysis of GENESIS Phase 3 Trial of Motixafortide (BL-8040) in Stem Cell Mobilization

BioLineRx launches mid-stage combo study in first-line pancreatic cancer

BioLineRx Ltd. has completed a Follow-on Equity Offering.

BioLineRx Ltd. to Report Q2, 2020 Results on Aug 06, 2020

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines